Table 4 Longitudinal studies in populations including sporadic Alzheimer's disease patients
From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Study | Subjects | Mean age at baseline (years) | Duration of follow-up (years) | Platform and antibodies | CV | Analyte associated with increased risk conversion to AD | Magnitude |
|---|---|---|---|---|---|---|---|
Mayeux et al. 1999 [30] | 105 CNs 64 CNp | 73.4 77.4 | 3.5 | ELISA 6E10 R182 R165 | - | High baseline Aβ1-42 | HR = 3.6-4.0 |
Mayeux et al. 2003 [27] | 365 CNs 86 CNp | 75.5 79.3 |  | ELISA 6E10 R182 R165 | - | High baseline Aβ1-42 | 1.9-2.4 |
van Oijen et al. 2006 [61] | 1364 CNs 289 CNp 103 CNp-OD |  | 8.5 | ELISA 6E10 R226 R209 | <15% | High baseline Aβ1-40 Low baseline Aβ1-42/Aβ1-40 | HR = 1.17 HR = 1.82 |
Graff-Radford et al. 2007 [58] | 510 CNs 53 CNp | - | 5 | ELISA BAN-50 BA27 BC05 | - | Low baseline Aβ1-42/Aβ1-40 | RR = 2.47-3.08 |
Lopez et al. 2008 [63] | 117 CNs 115 CNp 9 MCIs 33MCIp | 78.6 79.9 80.5 79.6 | 4.5 | ELISA | - | None | - |
Sundelöf et al. 2008 [62] | 608CNs 74 CNp | - | 11.2 | ELISA BNT77 BA27 BC05 | - | Low baseline Aβ1-40 (only in the cohort older than 77 at baseline) | HR = 4.9 |
Schupf 2008 [57] | 104 MCIp 1021 CNs | 80.7 76.3 | 4.5 | ELISA 6E10 R182 R165 | - | High baseline Aβ1-42 Decrease of Aβ1-42 Decrease of Aβ1-42/Aβ1-40 | HR = 2.3-3.5 HR = 2.6 HR = 3.4 |
Lambert et al. 2009 [59] | 985 CNs 233 CNp | 73.8 77.9 | 4 | xMAP INNO-BIA | - | Low baseline Aβ1-42/Aβ1-40 | HR = 2.0 |
Blasko et al. 2010 [78] | 122 CNs 33 CNp | - | 5 | ELISA INNOTEST | <17% | High baseline Aβ1-42 | OR = 1.7 |
Hansson et al. 2010 [13] | Â | Â | Â | xMAP INNO-BIA | <10% | No differences | Â |
Toledo et al. 2011 [10] | 162 MCIs 145 MCIp | 74.7 74.6 | 3.0 | xMAP INNO-BIA | <10% | None | Â |
Shah et al. 2012 [60] | 590 CNs 53 MCIp 24 MCIp-VaD | - | 15.8 | ELISA 2G3 21F12 | <20% | Low baseline Aβ1-40 Low baseline Aβ1-42 | HR = 2.1 HR = 1.6 |
Hansson et al. 2012 [29] | 677 CNs 37 MCIp 11 MCIp-VaD 5 MCIp-OD | 73.1 77.3 78.9 78.8 | 5 | xMAP INNO-BIA | <10% | High baseline Aβ1-40 | OR = 2.2 |